Introduction {#Sec1}
============

The rising prevalence of multi-drug resistant (MDR) bacteria has been attributed to increasing antibiotic use, as well as poor infection control in healthcare, farm, and community settings^[@CR1]--[@CR3]^. Due to the ubiquity of *Escherichia coli* in community, hospital, farm/food and environmental settings as well as in the gastrointestinal tract of humans and animals, they are used as index species to monitor the prevalence, types, and movement of resistance genes within and between clinical, farm, community and environmental settings^[@CR4]--[@CR6]^. Furthermore, the ability of *E. coli* to exchange genetic material with other bacterial species make them ideal candidates for studying the reservoir of resistance genes in any setting^[@CR7],[@CR8]^. Of equally grave concern is the presence of toxigenic and diarrheagenic *E. coli* strains that cause diarrhoea and substantial mortalities in several populations worldwide^[@CR4],[@CR5],[@CR9]--[@CR11]^.

Antibiotic-resistant *E. coli* has been described in foods, farms, animals, the environment and in clinical settings in South Africa, with varying resistance to colistin (*mcr-1*), carbapenems (NDM, OXA, KPC, IMP, and VIM), cephalosporins (TEM, SHV, OXA, and PER), fluoroquinolones (OqxAB, QnrA/B/C/S, AAC(6′)-Ib-cr, qepA, and mutations in *parCE* and *gyrAB*), tetracyclines (*tetA/B/C*), aminoglycosides etc.^[@CR3],[@CR12]--[@CR17]^. A recent report on third-generation cephalosporins and ciprofloxacin resistance in *E. coli* respectively found 27% and 30% resistance rates (Personal communication, Olga Perovic, 2019). As well, a study by Habte *et al*. (2009) on hospital- and community-acquired uropathogens found *E. coli* to be the most common (39%), and were mostly found to be producers of extended-spectrum β-lactamases (ESBLs)^[@CR18]^.

Globally, the spread of antibiotic resistance (ABR) has been attributed to the lateral transfer of genetic material^[@CR19]--[@CR23]^. Owing to the community- and healthcare-associated infections caused by *E. coli*, the exchange of multi-drug resistance in this species is of particular importance^[@CR9],[@CR12]^. Mobile genetic elements (MGEs) enable the transfer of ABR genes in *Enterobacteriaceae*^[@CR20]--[@CR22]^. Several MGEs have been described, including plasmids, which are circular, extra-chromosomal segments of DNA that can acquire insertion sequences, integrons and transposons to disseminate resistance genes^[@CR24]^. Integrons are genetic elements characterised by an *int* integrase site-specific gene, an *att1* recombination site and a *p* promoter gene that enables the transcription of cassettes, captured by the integron. Class 1 integrons are the most common and have been described in approximately 10% of sequenced bacterial genomes^[@CR25]^. Gene cassettes are within integrons, usually consisting of single, but sometimes multiple genes associated with resistance to more than one class of antibiotics^[@CR26],[@CR27]^. Integrons themselves are not mobile, lacking functions for self-mobility, and can be either chromosomal integrons, when found on the bacterial chromosome, or mobile integrons, when transposed on or associated with plasmids^[@CR28]^.

MGEs and ABR genes associated with *E. coli* have been well described globally but few studies have described the relationship between circulating MGEs and ABR genes in *E. coli* isolates from Africa, particularly South Africa. This study used whole-genome sequencing to identify MGEs, including integrons, plasmids and cassette arrays associated with MDR *E. coli* isolates in South Africa, determining their phylogenetic relationship with other South Africa, African and global isolates.

Materials and Methods {#Sec2}
=====================

Bacterial isolates {#Sec3}
------------------

The study sample consisted of twenty consecutive MDR *E. coli* isolates that were collected between April and November 2013 as part of a larger study where ESBL-producing Enterobacteriaceae, co-resistant to fluoroquinolones and aminoglycosides were collected from a referral laboratory that serves at least two secondary and three tertiary academic hospitals within the Gauteng province, South Africa. These isolates were collected from blood (n = 5), urine (n = 11), and unknown sources (n = 4) from patients having bacterial infections.

Identification and antimicrobial susceptibility testing {#Sec4}
-------------------------------------------------------

The isolates were isolated after growing them on blood agar and subsequently on Mueller-Hinton agar at 37 °C for 24 hours. They were then screened for ESBL production using cefoxitin, ceftazidime, and clavulanic acid antibiotic discs on Mueller-Hinton agar plates according to already reported protocols^[@CR6]^. The species and antimicrobial sensitivity of the isolates were determined with the MicroScan WalkWay7465 (Beckman Coulter California USA) using antibiotic panels involving 32 antibiotics: penicillins, cephems, carbapenems, polymyxins, fluoroquinolones, aminoglycosides, tetracyclines, tigecycline, sulphamethoxazole-trimethoprim, nitrofurantoin and fosfomycin (Table [S1](#MOESM1){ref-type="media"}). The MICs were interpreted according to the CLSI guidelines (CLSI M100 29^th^ Ed., 2019)^[@CR29]^, except for antibiotics such as colistin and tigecycline for which EUCAST (2019) breakpoints were used due to the absence of CLSI breakpoints^[@CR30]--[@CR32]^. The identification of the species was confirmed by the NCBI's ANI (average nucleotide identity) database.

Analysis of whole genome sequence data {#Sec5}
--------------------------------------

Whole-genome sequencing (WGS) was performed on the Ion torrent (Covaris, USA) and the Illumina Miseq (San Diego, USA) systems using already described methods^[@CR21],[@CR33],[@CR34]^. Briefly, the genomic DNA of the isolates were extracted and sheared to 200-bp libraries; 280-bp (for Ion Proton) and 350 bp (for Illumina Miseq) fragments were selected using 2% agarose gels and Pippen prep (Sage Science, Beverly, MA, USA). Individual libraries were pooled and sequenced on the Ion Proton (ThermoFisher, Waltham, MA, USA) or Illumina Miseq (San Diego, USA). The generated raw reads were de novo assembled using the SPAdes assembler.

Assembled sequences were annotated using ResFinder (<https://cge.cbs.dtu.dk/services/ResFinder/>) at default threshold ID (90%) and minimum length (60%) values to identify resistance genes. MLST 2.0 (<https://cge.cbs.dtu.dk/services/MLST/>) was used to identify the sequence types of the isolates. The INTEGRALL database (<http://integrall.bio.ua.pt/>) was used to identify integrons and gene cassettes within the genomic sequences. NCBI's PGAP^[@CR35]^, ISFinder (<https://isfinder.biotoul.fr/>) and the RAST SEEDVIEWER (<http://rast.nmpdr.org/seedviewer.cgi>) were used to annotate and identify the insertion sequences (ISs) and transposons bracketing the resistance genes. PlasmidFinder 2.1 (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) and pMLST 2.0 (<https://cge.cbs.dtu.dk/services/pMLST/>) were used to identify the plasmid replicons and incompatibility groups on the various contigs. The sequences have been deposited at GenBank under the Bioproject PRJNA355910, with the individual accession numbers delineated in Table [1](#Tab1){ref-type="table"}, S1 and S2. Mutations in *gyrAB, parCE, mgrB, pmrAB*, and *phoPQ* were manually curated from NCBI's BLAST by comparing the genomes of the isolates to wild type reference sequences^[@CR14]^.Table 1Patient demographics and resistance, virulence and plasmid replicon genes in the Escherichia coli strains.StrainAccession numberAge (yrs)GenderReferral hospitalSpecimenESBL\*MLST^†^Resistance genesVirulence genesPlasmidspMLST^‡^E003NXIZ00000000ND^§^M\*\*Tshwane AcademicBlood+^††^ST-744*strA, aadA5, strB, sul2, sul1, dfrA17, tet(B), catA1, blaCMY-2tsh, mchF, iroN, iss, gad*IncQ1IncF\[F16:A-:B1\], IncI1\[Unknown ST\]E005NXLF000000003MKalafongBlood+ST-131*strA, aac(3)-IIa, strB, aadA5, aac(3)-IId, mph(A), sul1, sul2, dfrA17, tet(A), catB3, blaCTX-M-15, blaTEM-1B, blaOXA-1, aac(6')Ib-crIha, gad, iss, ccI, senB, sat*IncY, ColRNAI, Col156, IncX4, Col(MG828)IncF\[F2:A2:B-\]E009NXLH000000003MKalafongBlood+ST-131*strA, aac(3)-IId, strB, aadA5, sul1, sul2, dfrA17, tet(A), catB3, blaCTX-M-15, blaTEM-1B, blaOXA-1, aac(6')Ib-crIha, gad, iss, ccI, senB, sat*IncY, ColRNAI, Col156, IncX4, Col(MG828)IncF\[F2:A2:B-\]E011NXKR000000007MTshwane AcademicUrine+ST-131*strA, aadA5, strB, aac(3)-IIa, mph(A), sul2, sul1, dfrA14, dfrA17, catB3, blaCTX-M-15, blaOXA-1, aac(6')Ib-crcnf1, iha, iss, gad*IncR, IncB/O/K/Z, Col156, ColRNAIIncF\[F31:A4:B1\]E013NXIN0000000063F^‡‡^KalafongUrine+ST-131*strA:strB:sul2:tet(A), blaCTX-M-27sat, iss, iha, gad*Col(BS512), Col156Col(MG828)IncF\[F1:A2:B-\]E019NXLG0000000066FTshwane AcademicND+ST-617*aadA5, aac(3)-IId, strA, strB, mph(A), sul1, sul2, dfrA17, tet(B), catB3, catA1, blaTEM-1B, blaCTX-M-15, blaOXA-1, aac(6')Ib-crIss, gad*Col8282, ColRNAIIncF\[F22\*:A4:B1\]E020NXJB0000000066FTshwane AcademicND+ST-617*strA, aadA5, aac(3)-IId, strB, mph(A), sul2, sul1, dfrA17, tet(B), catB3, catA1, blaCTX-M-15, blaTEM-1B, blaOXA-1, aac(6')Ib-criss, gad*Col8282, ColRNAIIncF\[F22\*:A4:B1\]E021NXIO0000000012FTshwane AcademicUrine+ST-131*aadA5, aac(3)-Ila, strA:strB, dfrA17:sul1:mph(A), sul2:tet(A), blaCTX-M-15, aac(6')Ib-cr:blaOXA-1:catB3gad, iha, iss, senB, gad, iha, iss, senB*Col156, Col(MG828)IncF\[F1:A1:B16\]E035NXJC0000000029FKalafongUrine+ST-10*aadA1, strA, strB, aph(3')-IIa, aadA2, sul1, oqxA, oqxB, dfrA12, tet(A), tet(B), cmlA1, blaTEM-1BkatP, cba, aaiC, astA, astA, gad*ColRNAIIncHI2\[ST-3\], IncN\[ST-1\], IncF\[F29:A-:B24\]E040NXIP0000000068FTshwane AcademicUrine+ST-95*fosA, aph(3')-IIa, aadA1:cmlA1:aadA2, strA:strB, sul2, sul3, dfrA5, blaCTX-M-14, blaTEM-1BmchF, ireA, gad, vat, iroN, iss, iss*IncQ1, Col156, Col(MG828)IncF\[F2:A-:B1\], IncHI2\[ST-3\]E053NXIR0000000053FKalafongUrine+ST-73*strA:strB:sul2, aac(3)-IIa, aph(3')-Ia, dfrA7:sul1, tet(A), catA1, blaCTX-M-15::blaTEM-1B, catB3:blaOXA-1:aac(6')Ib-crcnf1, mchF, iha, mchC, vat, iss, pic, iroN, senB, mcm, mchB*IncY, IncQ1, Col156IncF\[F87\*:A-:B10\]E056NXJD0000000049FTshwane AcademicND+ST-131*aac(3)-IIa, catB3, aac(6')Ib-cr, blaCTX-M-15, blaOXA-1, tet(A)sat, nfaE, iha, iss, gad*Col(BS512), Col156, ColRNAIIncF\[F4:A-:B52\]E057NXIS0000000057MTshwane AcademicUrine+ST-665*tet(A), blaCMY-2Tsh, mchF, iroN, iss, iss*IncI2, Col(MG828), ColRNAIIncF\[F-:A5:B1\], IncI1\[ST-12\]E058NXLI0000000072MKalafongND+ST-131*aac(3)-IIa, catB3, aac(6')Ib-cr, blaCTX-M-15, blaOXA-1, tet(A)sat, iha, iss, gad*Col(BS512), ColRNAIIncI1\[Unknown ST\]E060NXLJ0000000FKalafongUrine+ST-131*aac(3)-IIa, aadA5, strA, strB, mph(A), sul1, sul2, dfrA17, tet(A), catB3, blaCTX-M-15, blaTEM-1B, blaOXA-1, aac(6')Ib-crsat, nfaE, iha, iss, gad*Col(BS512)IncF\[F2:A1:B-\]E062NXJE0000000072MKalafongBlood+ST-131*tet(A), catB3, aac(6')Ib-cr, blaCTX-M-15, blaOXA-1sat, iha, iss, gad*Col(BS512), Col156, ColRNAIIncI1\[Unknown ST\]E063NXIT0000000034FKalafongUrine+ST-131*strA:strB, sul2, dfrA14, blaTEM-1B:blaCTX-M-15, tet(A)sat, iha, iss, gad*IncX1, IncB/O/K/Z, ColRNAIIncF\[F87\*:A4:B1\]K011NXKS0000000039FTshwane AcademicUrine+ST-410*ARR-2, strA, aac(3)-IIa, strB, aadA1, mph(A), sul2, sul1, dfrA23, tet(A), catB3, cmlA1, floR, blaOXA-10, blaCTX-M-15, blaOXA-1, aac(6')Ib-crlpfA, ccI*Col(MG828), IncA/C2, IncX4, ColRNAIIncF\[F31:A4:B1\]K075NXKJ0000000032FTshwane AcademicBlood+ST-648*strA, strB, aadA2, aph(3')-IIa, aadA1, fosA, sul3, tet(A), cmlA1air, gad, mchC, mchF, mchF, lpfA, iss, iss, eilA, tsh, iroN, mchB, astA, iha*Col8282, Col156, ColpVCIncF\[F18:A-:B1\], IncHI2\[ST-3\]K091NXKQ0000000059MTshwane AcademicUrine+ST-998*tet(B), sul1, dfrA1, blaTEM-1B, blaCTX-M-15, aadA1vat, cnf1, senB, iss, gad*Col8282, Col156IncF\[F1:A1:B23\]\*Extended-spectrum β-lactamase.^†^Multi-locus sequence typing.^‡^Plasmid MLST (multi-locus sequence typing).^§^Not detected, missing, or not tested for.\*\*Male.^††^ESBL-positive i.e., the isolate is an ESBL producer.^‡‡^Female.

Phylogenomic analysis {#Sec6}
---------------------

Whole-genome sequences of *E. coli* isolates curated at the PATRIC website (<https://www.patricbrc.org/>), between 2013 and 2018, including South African isolates, were downloaded and used alongside this study's isolates for the whole-genome phylogeny analysis to ensure a current epidemiological and evolutionary analysis (Dataset 1). The phylogeny of the *E. coli* isolates was characterised using Parsnp (<https://harvest.readthedocs.io/en/latest/content/parsnp.html>)^[@CR36]^ and edited with Figtree (<http://tree.bio.ed.ac.uk/software/figtree/>). Isolates of the same clade are highlighted with the same colour whilst those of the same countries have the same label (strain name) colours. The source of the strains viz., animal, environment and human, are shown with distinct colours and annotations. BacWGSTdb was used to type and associate the isolates to international clones, their resistance genes and clinical data^[@CR37]^. The resistome of strains of close phylogenetic relationship with this study's isolates were searched for using NCBI's Pathogen Detection database (<https://www.ncbi.nlm.nih.gov/pathogens/isolates#/search/>).

Results {#Sec7}
=======

Patient demographics and isolate characteristics {#Sec8}
------------------------------------------------

The 20 isolates were obtained from eight males and 12 females (Table [1](#Tab1){ref-type="table"}) within the ages of 3 and 72, from mainly blood (n = 5) and urine (n = 11). The isolates were all obtained from Kalafong (n = 9) and Steve Biko/Tshwane Academic (n = 11) tertiary academic hospitals, all based in Pretoria, South Africa.

Antibiotic susceptibility {#Sec9}
-------------------------

All the isolates were resistant to the penicillins (amoxicillin and piperacillin), and 3^rd^ and 4^th^ generation cephalosporins, but were susceptible to amoxicillin-clavulanate/sulbactam, piperacillin-tazobactam, cefotaxime-clavulanate, ceftazidime-clavulanate, cephamycin (cefoxitin), and carbapenems. For non-β-lactam antibiotics, almost all isolates were resistant to gentamicin, tobramycin, ciprofloxacin, levofloxacin, nalidixic, tetracycline, and sulphamethoxazole-trimethoprim (SXT), but were susceptible to amikacin and norfloxacin (they were however resistant to norfloxacin according to EUCAST breakpoints) (Supplementary Table [S1](#MOESM4){ref-type="media"}). Only eight isolates were resistant to minocycline whilst seven were resistant to chloramphenicol and four were resistant to colistin. Two isolates were categorically defined as resistant to tigecycline; however, the MICs (minimum inhibitory concentrations) of the remaining ten isolates (≤1 mg/L) are such that they could be either resistant (\>1 mg/L) or intermediate resistant (0.5 mg/L). All but two of the isolates were susceptible to fosfomycin and nitrofurantoin, which are important urinary tract infection (UTI) antibiotics^[@CR23],[@CR38]^. There was categorical agreement between the CLSI and EUCAST MIC breakpoint interpretations for all the isolates and all antibiotics except for norfloxacin (all isolates) and ceftazidime in only E003 (Supplementary Table [S1](#MOESM4){ref-type="media"}).

Genomic characteristics {#Sec10}
-----------------------

The genomic characteristics of the sequences, in terms of N50, L50, coverage, CRISPR arrays, coding sequences etc. are shown in Supplementary Table [S2](#MOESM4){ref-type="media"}. The draft genome size of the isolates ranged from 4.8 Mb to 5.5 Mb, with a GC content of 50.2--50.9; except for K091, the coverage of all the isolates were between 90 and 99 (Supplementary Table [S2](#MOESM4){ref-type="media"}).

Antimicrobial resistance genes and MGEs {#Sec11}
---------------------------------------

Overall, the *bla*~*CTX-M*~ gene was the most frequently identified in all the *E. coli* isolates. The *bla*~*CTX-M-15*~ gene was identified in 14/20 (70%) isolates. Two other isolates had the *bla*~*CTX-M-14*~ (E040) or the *bla*~*CTX-M-27*~ (E013) gene. The *bla*~*OXA*~ gene was detected in 12 isolates and isolate K11 encoded both *bla*~*OXA-1*~ and one *bla*~*OXA-10*~. The *bla*~*TEM-1B*~ gene was identified in 10 isolates. Nine isolates simultaneously harboured the *bla*~*CTX-M-15*~ and *bla*~*TEM-1B*~ genes. The isolates harboured all three β--lactamase genes. The *bla*~*CMY-2*~ gene was identified in two isolates, E003 and E057 (Table [1](#Tab1){ref-type="table"}), which were however susceptible to cefoxitin. In all these isolates, resistance to penicillins and cephems, except cefoxitin, was observed. However, the isolates became susceptible to the penicillins and cephalosporins in the presence of β-lactamase inhibitors (clavulanate, sulbactam and tazobactam). No carbapenemase genes were found, and carbapenem resistance was absent in all the strains (Table [1](#Tab1){ref-type="table"} and S1).

We identified only two types of plasmid-mediated quinolone resistance (PMQR) genes in the isolates (Table [1](#Tab1){ref-type="table"}). The *aac(6'*)*Ib-cr* gene was present in 12/20 (60%) isolates, whilst the *OqxAB* gene was present in only one isolate, E035. Q*nr* genes were absent. We identified mutations in the *gyrA, gyrB, parC* and *parE* quinolone resistance-determining region (*QRDR*) genes in all the isolates. *gyrA* had two mutations (A**828**S, D**678**E), *gyrB* had five (E**219**K, A**618**T, R**206**L, E**185**D and S**492**N), *parC* had seven (E**62**K, A**620**V, A**192**V, A**471**G, D**475**E and Q**481**H) and *parE* had three mutations (V**136**I, S**458**A, T**172**A) (Table [2](#Tab2){ref-type="table"}). One isolate (E053) had mutations in all the genes. The most frequent QRDR mutations were I**529**L in *parE*, S**80**1, E**84**V, A**192**V, A**471**G, and Q**841**H in *parC*, S**83**L, D**87**N, and E**678**D in *gyrA*, as well as D**185**E and A**618**T in *gyrB* (Table [2](#Tab2){ref-type="table"}). Sixteen (80%) isolates had mutations in all four QRDR genes. Except for E003, for which no PMQR gene was found, all the strains were resistant to at least three of the fluoroquinolones.Table 2Mutations in the gyrA, gyrB, parC and parE in the *E. coli* isolates.Isolate IDgyrAgyrBparCparEE003S83L, D87N, S828A, E678D\*D185E, E219K\*S80I, E475D, E62K\*, A620V\*I136VE005S83L, D87N, E678D\*D185E, A618T\*S80I, E84V, A192V\*, A471G\*, Q481H\*, E62K\*, D475E\*I529L, V136I\*E009S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, A192V\*, A471G, Q481H\*, E62K\*, A471G\*, D475E\*I529L, V136I\*E011S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\*, A192V\*, A471G\*, D475E\*, Q481H\*I529L, V136I\*E013S83L, D87N, E678DD185E, A618T\*S80I, E84V, A192V\*, A471G\*, Q481H\*I529LE019S83L, D87N, S828AD185ES80I, E475DI136V, S458A\*E020S83L, D87N, S828A, D678E\*D185ES80I, E475D, E62K\*I136V, S458A\*E021S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\*, A192V\*, A471G\*, Q481H\*I529LE035D678E\*, A828S\*D185E, R206L\*T718A\*, E62K\*, E475D\*V136I\*E040---E185D\*T718A\*, E62K\*, E475D\*V136I\*E053D678E\*, A828S\*E185D\*E62K\*, D475E\*V136I\*E056S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\*, A192V\*, A471G\*, Q481H\*, E62K\*, D475E\*I529L, V136I\*E057E678D, S828A,D185EE475D\*, E62K\*I136V,E058S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\*, A192V\*, A471G\*, Q481H\*, E62K\*, D475E\*I529L, V136I\*E060S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\*, A192V\*, A471G\*, D475E\*, Q481H\*I529L, V136I\*E062S83L, D87N, E678D, A828S\*D185E, A618T\*S80I, E84V, E62K\* A192V\*, A471G\*, D475E\*, Q481H\*I529L, V136I\*E063S83L, D87N, E678D, A828\*D185E, A618T\*S80I, E84V, E62K\* A192V\*, A471G\*, D475E\*, Q481H\*I529L, V136I\*K011S83L, D87N, S828A, E678DD185ES80I, E475D, E62K\*I136V, S458AK075S83L, D678E\*, A828S\*D185E, S492N\*, A618T\*, E656D\*R710C\*, E62K\*, D475E\*I136V, T172A\*K091D678E\*, A828S\*D185E, R206L\*T718A\*, E62K\*, D475E\*V136I\*\*Putatively novel mutations.

Aminoglycoside resistance genes *aac, aad* and *aph* were also identified. Fourteen (70%) isolates contained *strA* and *strB* genes (Supplementary Table [S1](#MOESM4){ref-type="media"}). Sixteen (80%) isolates had different *aad* genes; including *aadA5*, *aadA1* and *aadA2* (Tables [1](#Tab1){ref-type="table"} & [S2](#MOESM4){ref-type="media"}). Twelve (60%) isolates had *aac* genes: *aac(3*)*-IIa* (n = 8) and *aac(3)-IId* (n = 4). *aph* was found in four isolates: *aph(3')11a* (3/20, 15%) and *aph(3')1a* (1/20, 5%) genes. E063 was susceptible to all aminoglycosides, although it contained *strA* and *strB* genes. Furthermore, E035 and K091 both had *aadA*, but were susceptible to tobramycin (Table [1](#Tab1){ref-type="table"} & S1*)*.

Several isolates contained both *sul* and *dfr* genes, and were co-resistant to trimethoprim and sulfamethoxazole (Table [1](#Tab1){ref-type="table"} & S1). We identified *sul1* and *sul2* genes in 12/20 (60%) and 13/20 (65%) isolates, respectively. The *sul3* gene, rarely described in the literature, was identified in 2/20 (10%) isolates (E040 and K075). We identified the *dfr* gene in 11/20 (55%) isolates, specifically *dfrA17* (n = 8), *dfrA14* (n = 2) *dfrA1* (n = 1), *dfrA5* (n = 1), *dfrA7* (n = 1), *dfrA12* (n = 1) and *dfrA23* (n = 1). The *sul* and *dfr* genes occurred in diverse combinations in the isolates. In the two isolates with the *sul3* gene, the fosfomycin *fosA* resistance gene was also detected. E003, E056, E057 and E058 were susceptible to SXT, albeit E003 alone had *sul1, sul2* and *dfrA17* genes (Table [1](#Tab1){ref-type="table"} & S1*)*.

Ten tetracycline-resistant isolates had the *tet*(A) gene, and four isolates had the *tet*(B) gene. Among the two tetracycline-susceptible strains, E011 and E053, E053 harboured a *tet*(A) gene. The chloramphenicol acetylating transferase, *cat*, gene was detected in several isolates: 13/20 (65%) had *catB3* and four had *catA1*. The *cml* and *floR* efflux genes were identified in four and one isolate respectively, albeit only seven isolates expressed chloramphenicol resistance (Table [1](#Tab1){ref-type="table"} & S1). The *mph(A)* macrolide phosphotransferase gene was found alongside β-lactamases, *sul, cat, str* and aminoglycoside modifying enzyme genes in five isolates, whilst the rifampicin ADP ribosylating transferase *aar*2 gene was only identified in one isolate. In one multidrug-resistant isolate, we detected the chloramphenicol, macrolide and rifampicin resistance genes, together with those conferring resistance to aminoglycosides, fluoroquinolones, β-lactamases, tetracycline and trimethoprim/sulfamethoxazole.

Two isolates had increased colistin MICs, although only E035 had a chromosomal mutation (H**6**R) in the *phoQ* gene, but no mutation was detected in isolate E053. Other mutations were detected in *pmrB* (H**2**R, E**123**D, D**283**G and V**351**I) and *pmrA* (T**31**S, I**128**N and G**144**S) genes (Table [3](#Tab3){ref-type="table"}). No plasmid-mediated colistin gene mutations were detected in either isolate (Table [1](#Tab1){ref-type="table"}). The molecular mechanisms underlying tigecycline resistance in the two isolates remains unknown; no *tet(X)* resistance genes were found in the genomes^[@CR31],[@CR39]^. The resistome of all the isolates are found in Dataset 2.Table 3Colistin MICs and mutations in pmrB, pmrA, phoP, phoQ and mgrB in the *E. coli* isolates.Isolate IDMIC (mg/L)*pmr*B*pmr*A*pho*P*pho*Q*mgr*BE035\>4---Del RRHN (113--116), T31S\*, I28N\*, G144S\*---H6R---E053\>4H2R\*, E123D\*, D283G\*, V351I\*Del RRHN (113--116), T31S\*, I128N\*, G144S\*---------K0754D123E, I351V, A360VDel RRHN (113--116), S31T, N124I, S140G---H6R, L467MA8VK0914---Del RRHN (113--116)---H6R---\*Putatively novel mutations.

The most common plasmid replicon found in the genomes was IncF (n = 17, 85%). The isolates also contained the IncI (4/20, 20%), IncN (1/20, 5%) and IncH (3/20, 15%) replicons. Five (25%) isolates had more than one plasmid replicon (Table [1](#Tab1){ref-type="table"}). The E035 isolate had the IncH plasmid with an ln369 integron (Table [4](#Tab4){ref-type="table"}).Table 4Class 1 integrons, gene cassettes and sequence types found in the *Escherichia coli* isolates.Sample codeMLSTpMLSTIntegronCassette arraysGC1GC2GC3GC4GC5GC6E013ST131IncF---------------------E021ST131IncFln54*dfrA17aadA5*------------E040ST95IncFln13/641*dfrA5pspaadA2cmlA1aaadA1qacH2*E053ST73IncFln22*dfrA7*---------------E057ST665IncF---------------------E063ST131IncF---------------------E003ST744IncFln54*dfrA17aadA5*------------E020ST617IncFln54*dfrA17aadA5*------------E035ST10IncHln369*dfrA1baadA1b*------------E056ST131IncF---------------------E062ST131IncF---------------------K075ST648IncF---*estX3pspaadA2cmlA1aaadA1qacH2*K091ST998IncIln369*dfrA1baadA1b*------------E011ST131IncFln54*dfrA17aadA5*------------K011ST410---ln467*arr2cmlA1gblaoxa*---*10, aadA1e*---------E005ST131IncIln54*dfrA17aadA5*------------E019ST617IncFln54*dfrA17aadA5*------------E009ST131IncFln54*dfrA17aadA5*------------E058ST131IncF------------------E060ST131IncFln54*dfrA17aadA5*------------

Notably, *dfrA, aadA* and *QacEΔ1* genes were almost always found as gene cassettes within the class 1 integrons; all the isolates contained only class 1 integrons, which were associated with a variety of cassette arrays (Table [4](#Tab4){ref-type="table"}). The most frequently identified cassettes were *dfrA17* and *aadA5*, which were always associated with integron ln54 and MLST ST131. Cassette arrays *dfrA5-psp-aadA2-cmlA1a-aadA1-qac* and *estX3-psp-aadA2-cmlA1a-aadA1a-qac* were detected in isolates i.e., E040 and K075: *fosA* and *sul3* genes were identified in both these MDR isolates. Other integron types identified were ln369, ln22, ln13, ln54, ln467, ln641 and ln369. Isolate E040 had two integron types: ln13 and ln641.

As shown in Table [5](#Tab5){ref-type="table"}, most of the resistance genes were bracketed by either class 1 integrons, ISs and transposons or by all three. Composite and Tn3 transposons as well as IS6 insertion sequences were most common, with IS*Ec9* being commonly found with *bla*~CTX-M~ genes. The resistomes and mobilomes in these isolates were found to have between 98% and 100% sequence identity and length coverage with already deposited genome sequences at Genbank; the most common among these were *E. xiangfangensis* WCHEX045001 chromosome (CP043382.1) and *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1) (Table [5](#Tab5){ref-type="table"}).Table 5MGEs associated with antibiotic resistance genes in the *E. coli* strains.Strain (MLST)ContigSynteny of resistance genes and MGEsPlasmid/chromosomal sequence with closest nucleotide homology (accession number)E003 (ST744)36*sugE::bla*~*CMY-2*~*:IS*1380 *(ISEc9)Salmonella* Derby strain 116 plasmid (MK191846.1)73IS*1*:*catA1::Tn3(TnAs3)*:::*IntI1:dfrA17:ant(3")-Ia:QacEΔ1:sul1E. coli* 1223 chromosome (CP023383.1)99*aph(*6*)-Id:aph(3")-Ib:sul2E. coli* O111:H- 110512 plasmid pO111-110512_1 (AP019762.1)110*tet*(B):*tetR*:*ArsR:IS1E. coli* strain GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E005 (ST131)50*bla*~TEM-1B~:*IS1S. sonnei* 183660 plasmid p183660 (KX008967.1)51*Sul2:aph(3")-Ib:aph(*6*)-Id:relaxase:tetR:tet*(A):::*Tn*3*E. coli* Es_ST410_NW1_NDM_09_2017 plasmid pEsST410_NW_3 (CP031233.1)52*QacEΔ1:sul1::::resolvase:IS6 (IS6100)::tetR::mph(A)E. coli* CVM N56639 plasmid pN56639 (CP043753.1)67IS1380(ISEc9):*bla*~CTX-M-15~*E. coli* 1500 plasmid pEc1500_CTX (CP040270.1)70*aadA5:dfrA17:IntI1:IS6-like IS26E. coli* 131 plasmid p146-1 (CP041573.1)74*IS6-like IS26:catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5:IS6-like IS26E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E009 (ST131)51*bla*~TEM-1B~:IS*1Shigella sonnei* 183660 plasmid p183660 (KX008967.1)52*IS6 IS15DIV::::Sul2:aph(3")-Ib:aph(6)-Id::relaxase:tetR:tet*(A)*:::Tn3E. coli* Es_ST410_NW1_NDM_09_2017 plasmid pEsST410_NW_3 (CP031233.1)57*QacEΔ1:sul1:::::resolvase:IS6::tetRE. coli* CVM N56639 plasmid pN56639 (CP043753.1)68IS1380(IS*Ec9)*:*bla*~CTX-M-15~*E. coli* 1500 plasmid pEc1500_CTX (CP040270.1)70*aadA5:dfrA17:IntI1:IS*6*-like IS2*6*E. coli* 131 plasmid p146-1 (CP041573.1)74*IS*6*-like IS*26:*catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5: IS6-like IS*26*E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)79*aac(3)-IId::IS4E. coli* AR_0086 plasmid unnamed1 (CP032202.1)E011 (ST131)46IS*91:aph(*6*)-Id:aph(3'):dfrA14:aph(3")-Ib:sul2E. coli* Ec20-Lar plasmid unnamed (MK396099.1)63*IntI1:dfrA17:aadA5:QacEΔ1:::::resolvase:*IS6*::tetR::mph*(A):IS*6E. coli* Ecol_AZ146 plasmid pECAZ146_1 (CP018990.1)88IS*6*:Tn*3*::*bla*~CTX-M-15~::IS*1380E. coli* Ecol_AZ146 chromosome (CP018991.1); *E. coli* 219 plasmid unnamed (CP020515.1)96*aac(3)-IIa*::IS3:IS6*E. xiangfangensis* WCHEX045001 chromosome (CP043382.1)103IS6*:catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5:IS6*E013 (ST131)60IS*6*IS*15DI:tet(A):tetR::aph(6)-Id:aph(3")-Ib:sul2:*IS*6*(IS*15DIV)E. coli* strain H105 plasmid pH105 (CP021871.1)79IS*6-*like (IS*26):bla*~*CTX-M-15/27*~*:IS6-like* (*IS26*)*E. coli* strain 131 plasmid p146-1 (CP041573.1)E019 (ST617)64*IntI1:dfrA17:AadA5:QacEΔ1:sul1:::::resolvase:IS6::tetR::mph*(A)::IS*6*-like(IS*26*)*E. coli* VRES-hospital6495150 plasmid: 1 (LR595886.1)74IS91*::::::sul2:aph(3")-IbS*. Manhattan SA20084699 plasmid unnamed2 (CP022499.1)76Tn*3::bla*~*CTX-M-*1*5*~*:IS1380 (ISEc9)K. pneumoniae* FDAARGOS_447 plasmid unnamed3 (CP023950.1)77IS*1::::tetR:tet*(B):*tet*(C):*:*IS*4 (ISVsa5)S. flexneri* FDAARGOS_535 chromosome (CP034060.1)79*RepA:*IS*6(*IS*15DIV)*:Tn*3::catA1:IS1E. coli* 675SK2 plasmid p675SK2_B (CP027703.1)87IS6-like IS*26*:::::*aac(3)-IId::IS4K. pneumoniae* PIMB15ND2KP27 plasmid pKP27-NDM4 (CP041642.1)97IS*6-*like IS*26:aac(6')-Ib-cr5:bla*~*OXA-1*~*:catB3:IS6-like (IS26)E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E020 (ST617)69IS*6*::*IntI1(In54):dfrA17:aadA5:QacEΔ1:Sul1::::::IS6:tetR:tet:mph(A):*IS*6Shigella flexneri* ID134382 plasmid pSf1 (MG767300.1)82*Sul2:aph(3")-Ib:aph(6)-Id:*IS*91E. coli* WCHEC005237 plasmid p1_005237 (CP026572.2)83*bla*~TEM-1B~:IS*1E. coli* plasmid pI1-34TF (LN850163.1)84IS6 (IS*15DIV)*:Tn3::*bla*~CTX-M-15~:IS1380 (ISEc9)::IS6*K. pneumoniae* FDAARGOS_447 plasmid unnamed3 (CP023950.1)88IS1::::*tetR*:*tet*(B):*tet*(C)*:*IS4*S. enterica Wien ZM3 plasmid pZM3* (MK797990.1)89IS6 (IS*15DIV*)::Tn3(Tn*As3)*:*catA1E. coli* 6*75SK2 plasmid p*6*75SK2_B* (CP027703.1)105IS*6:catB*3*:bla*~OXA-1~:*aac(*6*')-Ib-cr5:*IS*6E. coli* strain GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E021 (ST131)56IS6-like (IS26)::*mph*(A)::*tetR::: IS6-like IS6100::::::sul1:QacEΔ1:aadA5:dfrA17:IntI1(In54)E. coli* 131 plasmid p2629-1 (CP041542.1)62IS*6*(IS*15DIV)*:::*sul2:aph(3")-Ib:aph(6)-Id::tetR:tet*(A)*::::IS6* (*IS15DI)E. coli* strain 4/4 plasmid p4_4.1 (CP023827.1)82IS1380-like (ISEc9):*bla*~CTX-M-15~::Tn*3*-like Tn3 family*E. coli* CFSAN061761 chromosome (CP042903.1); plasmid: *K. pneumoniae* p14ARS_VSM0843-1(LR697132.1)84IS*6*-like(IS26):IS3 family::*aac(3)-IIa:*IS*6-*like IS26*E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* Ec-050 plasmid pEc-050-NDM-5 (CP043230.1)90IS6-like IS26:*catB3:bla*~*OXA-1*~:*aac(6')-Ib-cr5*:IS6-like IS26*E. xiangfangensis* WCHEX045001 chromosome (CP043382.1)E035 (ST10)36*IS3:IS21(IS1326):::sul1:QacEΔ1:AadA1:dfrA1:IntI1E. coli* O16:H48 strain PG20180175 plasmid pPG20180175.1-IncAC2 (CP043190.1)41*bla*~TEM-1B~:recombinase::IS1380(IS*Ec9)*:*bla*~CTX-M-15~::Tn*3:*IS1*S. Typhi* WGS1146 plasmid unnamed (CP040574.1)130*ArsR*:*tetR:tet*(B):*:*Is1*E. coli* strain CFSAN061761 chromosome (CP042903.1)E040 (ST95)55IS256:QacL:aadA1:CmlA1:AadA2:::*IntI1*:::Tn3-like Tn*As1E. coli* CFSAN061772 plasmid pCFSAN061772_02 (CP042895.1)83IS26 (*tnpA*26):*sul3:::mefB-*IS26*:tnpA*26*E. coli* F2_14D plasmid pF2_14D_HI2 (MK461931.1)84IS*26*:*repA*-IS*26*:*repC:sul2:strAE. coli* 2009-52 plasmid pSDJ2009-52F (MH195200.1)86IS4:*aph(3')-IIaE. coli* NCYU-25-82 plasmid pNCYU-25-82-7 (CP042634.1)89IS91:*bla*~TEM-1B~*E. coli* O111:H- 110512 plasmid pO111-110512_1 DNA (AP019762.1)91*IS6-like IS26::fosA3*:IS5/IS1182*E. coli* AR Bank \#0349 plasmid pAR349 (CP041997.1)99*aph(6)-Id:aph(*3*")-IbE. coli* CVM N16EC0140 plasmid pN16EC0140-1 (CP043748.1)107IS5/IS1182:*bla*~CTX-M-14~::IS6-like IS26*E. coli* AR Bank \#0349 plasmid pAR349 (CP041997.1)119*IntI1:dfrA5:IntI1-IS26E. coli* 2009-52 plasmid pSDJ2009-52F ()E053 (ST73)45Tn*3*::*tetR:tet*(A)::::::::::::IS110::::IS21*E. coli* PU-1 chromosome (CP042246.1)60IS6:Tn3::*bla*~CTX-M-15~:IS1380 (IS*Ec9)E. cloacae* NH77 chromosome (CP040827.1)77*aph(6)-Id:aph(*3*")-Ib:sul2E. coli* FDAARGOS_772 chromosome (CP041002.1)80Tn3-like (TnAs3):::IntI1:*dfrA7:QacEΔ1::IS6* (*IS15DIV)E. coli* O104:H4 FWSEC. 0009 chromosome (CP031902.1)93IS6::aac(3)-IIa::IS*3E. xiangfangensis* WCHEX045001 chromosome (CP043382.1)103IS6-like IS26:*catB*3*:bla*~*OXA-1*~:*aac(6')-Ib-cr5:IS6-like IS26*110Tn3:*catA1S. enterica Wien ZM3 plasmid pZM3* (MK797990.1)137IS6:*aph(3')-IaK. pneumoniae* WCHKP7E2 plasmid pCMY2_085072 (CP028804.2)E056 (ST131)53*tetR:tet*(A)::*Tn1721:resolvase:Tn5403:Tn5403:::Tn2 tnpAE. coli* strain 661 (LT985271.1)84IS1380-like IS*Ec9*:*bla*~CTX-M-15~::Tn*3*-like Tn3*E. coli* strain CFSAN061761 chromosome (CP042903.1)97*IS6-like IS26:IS3::aac(3)-IIa:IS6-like IS26E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)102IS6-like IS26*:catB3*:*bla*~0XA-1~:*aac(6')-Ib-cr5: IS6-like IS26*E057 (ST665)18IS1380 IS*Ec9:bla*~CMY-2~::*sugESalmonella* Derby strain 116 plasmid (MK191846.1)72*Tn*3:::*tet*(A):*tetR:*relaxase*E. coli* plasmid pHN32wt (MH450052.1)E058 (ST131)42*Tn*3*:::Tn*3*:resolvase:Tn*3*:::tet(A):tetRE. coli* 661 plasmid: RCS59_p (LT985271.1)51*Tn3::bla*~*CTX-M-15*~*:IS*1380 *ISEc9K. pneumoniae* FDAARGOS_447 plasmid unnamed3 (CP023950.1)61IS3*:aac(*3*)-IIaE. coli AR21*6*.2b* plasmid pMPNDM-5 (CP043944.1)66*IS6-like IS*26*:catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5:IS6-like IS26E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E060 (ST131)14Tn*3:resolvase*:Tn3:::*tet*(A):*tetRE. coli* 4/0 chromosome (CP023849.1)26*bla*~TEM-1B~:recombinase:Tn3*E. coli* 131 plasmid p2448-1 (CP041547.1)39IS1380 ISEc9:*bla*~CTX-M-15~::Tn*3E. coli* 131 chromosome (CP041581.1)43*IntI1*:*dfrA17:aadA5:QacEΔ1:sul1:::::resolvase:*IS*6::tetR::mph*(A)*E. coli* VRES-hospital6495150 plasmid: 1 (LR595886.1)52IS91*::::::sul2:aph(3")-Ib:S*. Manhattan SA20084699 plasmid unnamed2 (CP022499.1)66IS3*:aac(3)-IIaE. coli* AR216.2b plasmid pMPNDM-5 (Sequence ID: CP043944.1)70*catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5:resolvaseE. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *E. coli* GZ04-0086 plasmid pCTXM-GZ04 (CP042337.1)E062 (ST131)52*tetR:tet*(A):::Tn*3* family::Tn*3* family:::Tn*3* family*E. coli* 661 plasmid: RCS59_p (LT985271.1)70IS*1380* family IS*Ec9*:*bla*~CTX-M-15~::Tn*3* family*K. pneumoniae* FDAARGOS_447 plasmid unnamed3 (CP023950.1)83IS*6*-like IS*26*:*catB3:bla*~*OXA-1*~:*aac(6')-Ib-cr5:IS6-like IS26E. xiangfangensis* WCHEX045001 chromosome (CP043382.1); *K. pneumoniae* 18-2374 plasmid pSECR18-2374A (CP041928.1)E063 (ST131)25IS91:*aph(6)-Id:aph(3')-Ib:dfrA14:aph(3")-Ib:sul2*::::::::: *bla*~*TEM-1*~:::IS1380 ISEc9:*bla*~CTX-M-15~::Tn3 family*E. coli* Ecol_AZ161 plasmid pECAZ161_1 (CP019011.1)72Tn3 family:::*tet*(A):*tetR:relaxase:Tn3 familyE. coli* Ec-050 plasmid pEc-050-NDM-5 (CP043230.1)K011 *(ST410)*19*aph(6)-Id:aph(3")-Ib:sul2K. pneumoniae* PIMB15ND2KP27 plasmid pKP27-MCR1 (CP041641.1)52*IntI1:Arr-2:CmlA5:bla*~*OXA-10*~*:aadA1:QacEΔ1:sul1:IS91:::dfrA23:::: IS110:Tn3:resolvase::IntI1:repAE. coli* C600_pConj125k plasmid pConj125k (MK033499.1)71*Resolvase*::IS*91:floR:lysRE. coli* O16:H48 PG20180173 plasmid pPG20180173.1-IncAC2 (CP043192.1)76*IS6::tetR::mph*(A)*K. pneumoniae* 555 plasmid pSCKLB555-4 (CP043936.1)78IS1380:*bla*~CTX-M-15~::*Tn*3*E. coli* 219 plasmid unnamed (CP020515.1)80*Tn3:::tet(A):tetR:relaxaseE. coli* CVM N16EC0879 plasmid pN16EC0879-1 (CP043745.1)84IS*3::aac(3)-IIaE. coli* strain AR216.2b plasmid pMPNDM-5 (CP043944.1)86*catB3:bla*~*OXA-1*~*:aac(6')-Ib-cr5:resolvaseE. xiangfangensis* WCHEX045001 chromosome (CP043382.1);K075 (ST648)78*IS6:IntI1::aadA2:CmlA1:aadA1:QacL:IS256:IS6S*. Typhimurium sg_wt7 chromosome/plasmid (CP036168.1)83IS5/IS1133-like IS903B:IS*3*:*aph (3")-Ib:aph(6)-Id*94*aph(3')-IIa:*IS4::IS91 family*E. coli* 13P477T plasmid p13P477T-7 (CP021103.1)96Tn3-like Tn*As1::tet*(A):*tetR::Tn3 familyE. coli* CVM N16EC0879 plasmid pN16EC0879-1 (CP043745.1)111IS*2*6*:sul3::mefB-IS26E. coli* F2_14D plasmid pF2_14D_HI2 (MK461931.1)122IS5/IS1182:*fosA3*::IS*6E. coli* AR Bank \#0349 plasmid pAR349 (CP041997.1)143IS5/IS1182:*bla*~CTX-M-14~::IS6-like IS26*E. coli* 1106 plasmid p1106-IncHI2 (MG825373.1); *E. coli* AR Bank \#0349 plasmid pAR349 (CP041997.1)K091 (ST998)37IS6*:IntI1:dfrA1:aadA1:QacEΔ1:sul1::::IS21 IS1326:IS3:::*IS*6E. coli* O16:H48 PG20180173 plasmid pPG20180173.1-IncAC2 (CP043192.1)41*bla*~*TEM-1*~*:recombinase::IS1380 ISEc9:bla*~*CTX-M-15*~*::Tn3:IS1E. coli* ECONIH6 plasmid pECO-6dfa (CP026200.1)54*ArsR:tetR:tet*(B):*:IS1E. coli* CFSAN061761 chromosome (CP042903.1)

Sequence types and phylogenomics {#Sec12}
--------------------------------

The *E. coli* isolates were multiclonal, with ST131 (n = 10), ST617 (n = 2) and singletons of ST10, ST73, ST95, ST410, ST648, ST665, ST744 and ST998 being identified (Tables [1](#Tab1){ref-type="table"}, [4](#Tab4){ref-type="table"} & 5). The two ST617 strains (E019 and E020) virtually have the same plasmid replicon types, resistome, virulome, integron types, genomic features and patient characteristics (66-year old female from Tshwane Academic hospital). A slightly similar observation was also made for isolates E005 and E009 (ST131). However, these patterns were not observed among the other strains of ST131 that had different patient demographics (different sexes, ages and hospitals) (Figs [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"})Figure 1A neighbour-joining phylogenetic tree of African *E. coli* isolates. (**A**) The annotations show that the S. African strains used in this study were basically related to strains from Tanzania and Egypt. Strains of same and different clones clustered together in many instances, with isolates of the same clone only clustering together in a few instances. (**B**) The strains clustered according to sequence types, with ST131 and ST617 strains being on the same branches. However, ST10 and ST998 were also found on the same branch, showing the higher resolution of whole-genome MLST over conventional MLST.Figure 2A neighbour-joining phylogenetic tree of global *E. coli* isolates depicting lineages between the Pretoria (South Africa) sequences in red clusters, Durban (South Africa) sequences in blue clusters and international sequences. The S. African strains were mainly related to strains from the UK.

The phylogenomic analyses of the isolates showed that they were more closely aligned to strains from Tanzania and Egypt than to any other country; none of the isolates were phylogenetically related to any strain from South Africa. Specifically, E019 and E0120 (ST617), described above to have the same resistome, mobilome, virulome, genomic and demographic features, as well as K091 (ST998) and E035 (ST10), were found to be on the same clade/node whilst E005 and E009, found to also have very similar genomic characteristics, were distantly placed on different branches on the tree (Figs [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Dataset 1). E062, E056 and E058, as well as E005 and E011, all ST131, clustered together on one branch and clade. However, ST131 strains such as E063 and E060 were distant from other ST131 strains; other STs such as E003 (ST744), E057 (ST665) and K011 (ST410) were not closely related to any strains on the tree (Fig. [1A](#Fig1){ref-type="fig"}; Supplementary Dataset [1](#MOESM4){ref-type="media"}).

K075 was on the same clonal node as CFSAN061771 (ST1485) from Egypt and same clade/branch as CFSAN061765 (ST1722:*bla*~CMY-2~, *bla*~EC~, *bla*~OXA-244~), also from Egypt. E040 and RDK06_554 (Tanzania: *aph(*3*")-Ib, aph(6)-Id, bla*~EC~*, bla*~TEM-1~, *dfrA5, sul2*), E053 and R0004_118A (Tanzania ST73: *aph(3")-Ib, aph(6)-Id, bla*~EC-5~, *bla*~TEM-1~, *dfrA7, qacEΔ1, sul1, sul2*), E021 and RDK40_71E (Tanzania, ST131: *aac(3)-IIa, aac(6')-Ib-cr5, aadA5, aph(3")-Ib, aph(6)-Id, bla*~CTX-M-15~, *bla*~EC~, *bla*~OXA-1~, *catB3, dfrA17, mph(A), qacEdelta1, sul1, sul2*, *tet*(A)), as well as E009 and RDK02_567B (Tanzania ST10: *aadA5, bla*~CTX-M~*, bla*~EC~*, dfrA17, mph(A), qacEΔ1, sul1*), were all closely related on the same clonal branches. Globally, the strains were closely related to strains from mainly the UK (Fig. [2](#Fig2){ref-type="fig"}), including *E. coli* 05:H4 strain ECO0291 (with E057) and *E. coli* 021:H52 strain ECO0336 (with E003), all of phylogroup A. Evidently, the STs and resistance genes between this study's isolates and those from Egypt and Tanzania were different.

Virulome {#Sec13}
--------

A total of 24 virulence genes (Table [1](#Tab1){ref-type="table"}) were recorded in all the isolates combined, with E053 (n = 11 virulence genes) and K075 (n = 12 virulence genes) having the most repertoire of virulence genes; K011, E019 and E020 had the least (n = 2 virulence genes). Virulome similarity could be seen between isolates belonging to the same clone than between those of different clones. E035 (ST10) and E040 (ST95) had unique set of virulence genes, whilst K075 and E053 had very diverse set of virulence genes. The commonest virulence genes among the strains were *iss* (n = 18 isolates)*, gad* (n = 17 isolates) and *iha* (n = 12 isolates), with *katP, cba, aaiC, ireA, pic, mcm, air*, and *eilA* occurring in single isolates (Fig. [3](#Fig3){ref-type="fig"}; Supplementary File [2](#MOESM4){ref-type="media"}). A specimen source-virulome association comparison was made (Fig. [4](#Fig4){ref-type="fig"}; Supplementary file [2](#MOESM4){ref-type="media"}) and there was little evidence to suggest that strains from blood had more virulence genes than those from urine, albeit the strain with the most virulence genes was from blood. *eilA, air*, and *lpfA* were only found in a single strain (K075) from blood.Figure 3Frequency distribution of virulence (virulome) genes found per *Escherichia coli* isolate. Several virulence genes were found in the isolates, ranging from two to 24. Some isolates had more virulence genes diversity than others, with some virulence genes being found in only an isolate from blood (K075).Figure 4Association between the virulome and specimen source of each *Escherichia coli* isolate. The isolate with the highest virulome composition and diversity was from blood (K075) followed by one from urine (E053). Thus, there is little to suggest that isolates from blood had more virulence genes than those from urine as shown in the chart.

Discussion {#Sec14}
==========

In this study, 20 clinical *E. coli* isolates showed an extensive repertoire of resistance genes bracketed by composite Tn*3* transposons, ISs and class 1 integrons on contigs containing mainly IncF plasmid replicons in multiclonal and same clone strains. The strains can be rightly defined as MDR strains due to their phenotypic resistance to penicillins, cephalosporins, aztreonam, fluoroquinolones, aminoglycoside, tetracycline and SXT. The ESBL phenotypes of the strains, as confirmed by the disc synergy test, was confirmed by the presence of ESBL genes (*bla*~CTX-M~, *bla*~OXA~, and *bla*~TEM-1B~) and the susceptibility of the strains to the β-lactamase inhibitors viz., clavulanic acid, sulbactam and tazobactam, when combined with either the penicillins or cephalosporins. A major observation was the cefoxitin susceptibility of E003 and E057, both of which harboured *bla*~CMY-2~ within the same genetic context of IS1380 IS*Ec9:bla*~CMY-2~::*sugE* (the reverse orientation was found in E003) that was of closest nucleotide identity with *Salmonella* Derby strain 116 plasmid (MK191846.1). Whereas the genetic context of these *bla*~CMY-2~ suggests that they might have been acquired horizontally, the host strains could not show phenotypic resistance to cefoxitin as expected of strains with acquired *bla*~CMY-2~^[@CR40],[@CR41]^.

Moreover, AmpC β-lactamases such as *bla*~CMY-2~ are not expected to be inhibited by β-lactamase inhibitors (clavulanate, sulbactam and tazobactam) as was observed in E003 and E057, which were susceptible to β-lactam/β-lactamase inhibitor combinations. These observations strongly suggest that the *bla*~CMY-2~ genes in these two isolates might not have been expressed or were not active in the isolates^[@CR40],[@CR41]^. Besides these two isolates, other resistance discrepancies were observed between the phenomes and genomes of other isolates that harboured resistance genes but did not express resistance phenotypically. Examples include the susceptibility of E063, E035 and K091 strains to tobramycin although they had *aadA, aph(3')-IIa, or strA/B* genes. Other such discrepancies, already stated in the results above, can be found by studying Supplementary Tables [1](#MOESM4){ref-type="media"} and [2](#MOESM4){ref-type="media"}.

The *bla*~*CTX-M-15*~ gene, surrounded by composite transposons mostly including IS*Ec9*, was found in almost all the *E. coli* isolates, which is higher than that reported by two other studies from South Africa where 45% and 59% of isolates in Port Elizabeth and Cape Town, respectively, possessed this gene. Furthermore, the co-existence of *bla*~*OXA-10*~ and *bla*~*TEM*~ genes is consistent with observations in local studies^[@CR17],[@CR42]^ as well as in studies from China^[@CR42],[@CR43]^. Similarly, the co-occurrence of *aac(6')Ib-cr* and *bla* ~*CTX-M-15*~ are consistent with observations made in isolates from China and the USA^[@CR44],[@CR45]^. IS*Ec9* and IncF plasmids have been implicated in the mobilization and dissemination of *bla*~*CTX-M-15*~ globally^[@CR20],[@CR21],[@CR45],[@CR46]^; the IncF plasmids mobilizing *bla*~*CTX-M-15*~ also co-harboured *aac(6')Ib-cr, bla*~*OXA-10*~ and *bla*~*TEM*~ genes within *E. coli* ST131^[@CR46]^. Our findings support this global data and shows that these resistance genes are both clonally and horizontally disseminated.

Unfortunately, the individual effects of the various mutations found in the QRDR of *parCE* and *gyrAB* as well as in *mgrB, pmrAB*, and *phoPQ*, in conferring resistance to fluoroquinolones and colistin could not ascertained in this study. This limitation makes it difficult to determine which resistance mechanism underlies the observed resistance, particularly as PMQR genes were also found in some of the isolates. The mutations observed in the *parCE* and *gyrAB* genes were not found in isolates that were reported from Durban, South Africa, except for R206L and E185D (in *gyrB*) and S458A in *parE*^[@CR14]^. Similar studies in Portugal and India reported similar QRDR mutations^[@CR47],[@CR48]^ (Table [2](#Tab2){ref-type="table"}). We did not find *qnr* genes in the isolates, although a similar work in Durban reported several *qnr* variants^[@CR14],[@CR49],[@CR50]^. However, the presence of *OqxAB* efflux genes have been reported in bacterial isolates from South Africa^[@CR14]^.

*tet* genes are commonly reported from South Africa, Africa and worldwide on chromosomes or plasmids alongside *bla*~*CTX-M-15*,~ *aac(6*′)*Ib-cr, bla*~*OXA-10*~ and *bla*~*TEM*~^[@CR22],[@CR51]--[@CR53]^; specifically, the *tet(A/B)* genes in these isolates were mostly bracketed by Tn3 and composite transposons as well as by ISs. Despite chloramphenicol rarely being used to treat *E. coli* infections, several isolates contained the *cat* gene, indicating co-selection and/or transmission of chloramphenicol resistance genes by other antibiotics. Notably, all *catB3* genes were found as *catB3:bla*~*OXA-1*~*:aac(*6*')-Ib-cr5* within composite transposons, suggesting that the use of fluoroquinolones, aminoglycosides and β-lactams could co-select and drive the dissemination of this resistance gene even in the absence of phenicols. Moreover, *cat* genes have been shown to be co-transmitted on plasmids with *aad* and *sul* genes through horizontal transmission and not natural selection^[@CR54]^. Notably, *sul* and *aad* genes were identified in 9/11 (82%) of the isolates in which the *cat* gene was also identified.

The *sul* and *dfr* gene cassettes identified in the isolates were previously reported in a study done in *Enterobacteriaceae* in Tunisia^[@CR55]^. However, these genes have only been reported in *Streptococcus pneumoniae* isolates from South Africa^[@CR56]^, whilst the rare *sul3* gene was only recently reported in clinical isolates in Tanzania^[@CR57]^. The genetic environment of *sul*1 *and sul2* genes were mostly consistent, with *sul*1 being mostly associated with *QacEΔ1* and *aadA* genes (*aadA1/5:QacEΔ1:sul1*) and *sul2* being always found with *aph* genes (*aph(6)-Id:aph(3*′)*-Ib:sul2*) within composite transposons or ISs. The association of these genes on the same MGEs might explain the co-resistance to SXT, chloramphenicol and macrolides in these strains as these antibiotics are not prescribed for treatment of infections caused by *E. coli* in South Africa.

Although *mph*(A), which is responsible for macrolide resistance, is not clinically important in *Enterobacteriaceae*, they can be transferred to medically important Gram-positive bacteria for which macrolides are indicated^[@CR58]^. The *mph*(A) gene were normally found alongside *tetR* and IS*6* (*IS6::tetR::mph*(A)). The simultaneous presence of *cat, mph*(A) and *floR* genes in clinical *E. coli* isolates in South Africa has not been previously described, although similar findings were reported from Nigerian poultry and American calves^[@CR59],[@CR60]^.

The frequency of class 1 integrons in these strains (95%) was much higher than isolates reported from Tunisia (64%), India (61%) and Korea (54%)^[@CR61]--[@CR64]^. The dominance of the *dfrA17* and *aadA5* cassettes, conferring resistance to trimethoprim and streptomycin, respectively, and their association with class 1 integrons has been described in several countries worldwide but not South Africa^[@CR26],[@CR62],[@CR65],[@CR66]^. The isolates contained seven different cassette arrays, more than previously described from any single location^[@CR65]^. We also identified the β-lactamase *bla*~*OXA-10*~ cassette in one isolate, which was previously described in a South China study^[@CR43]^. We found no cassettes encoding *bla*~CTX-M~ and *bla*~TEM~, confirming that these genes are rarely spread by integrons. The integrons carrying the *dfrA5-psp-aadA2-cmlA1a-aadA1-qac* (E040) and *estX3-psp-aadA2-cmlA1a-aadA1a-qac* (K075) cassette arrays are the first to be described in Africa. There is a close similarity between the arrays of these two integrons, although their host strains were of different STs, and their resistomes and mobilomes were different (Tables [1](#Tab1){ref-type="table"} and [5](#Tab5){ref-type="table"}); further analysis would be required to clarify this similarity.

As shown in Table [5](#Tab5){ref-type="table"}, all the class 1 integrons were bracketed by ISs and composite transposons that can mobilize these resistance genes from plasmids to chromosomes and vice versa. The synteny and localization of several resistance genes within these MGEs suggest the presence of resistance genomic islands within the genomes. However, the transferability of these genes and MGEs were not experimentally ascertained, although the horizontal transmission of these resistance genes through MGEs within and across species cannot be entirely ruled out. Further, the close sequence identity of the contigs bearing the resistance genes and MGEs with already known plasmids and chromosomes confirms the location of these contigs on either chromosomes or plasmids.

The resolving power of WGS over MLST (multi-locus sequence typing) is clearly observed in Figs [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} in that strains of the same STs were found on different branches and nodes. The demographics, virulome, resistome, mobilome and genomic features of E005 and E009 as well as of E019 and E020 suggest that they might have originated from the same patients. Although 10 isolates were of ST131, only three (E062, E056 and E058) and two (E095 and E011) groups were phylogenetically related on the same clade, with the others clustering with other strains of different STs. These differences were further seen between this study's isolates and those from Egypt and Tanzania, with which they closely clustered (Fig. [1](#Fig1){ref-type="fig"}). As seen in Fig. [2](#Fig2){ref-type="fig"}, they also varied in ST from those from the UK. These seeming discrepancies is due to the lower resolving power of MLST, which only uses seven house-keeping genes to type bacteria.

In addition, the difference in resistance genes between the closely clustered strains from South Africa and Egypt and Tanzania, further shows that not all these resistance genes were chromosomal. This is because the phylogenetic tree was drawn with the core genomes of the individual isolates without their accessory genomes (plasmids)^[@CR37]^. The absence of any close relationship between the isolates in this study and other South African strains demonstrates the absence of an intra-country dissemination of *E. coli;* however, further investigations are necessary to confirm this assertion. Interestingly, the isolates were closely related to strains from Egypt, Tanzania and UK, suggesting the possible exchange of people between South Africa and these countries. Therefore, it is necessary for public health officials to screen patients coming from other countries (for medical tourism) for resistance genes to reduce the exchange of resistance genes across borders^[@CR3]^.

The diversity and multiplicity of virulence genes found in these isolates, that were mainly obtained from blood and urine, is quite concerning. This is more so as the isolates were also MDR. Evidently, the small sample size of strains made it impossible to obtain a better association between specimen source and the virulome as suggested by Irenge *et al*.^[@CR67]^. However, it is worthy of consideration, that isolates from the urine would also need virulence genes to initiate infection; hence, it is not surprising that the virulome of urine and blood isolates were comparable. Thus, it would be better to rather compare clinical with environmental strains in terms of virulence. The diversity and complexity of the virulome found in this study is quite comparable to that reported recently from the DRC^[@CR67]^, although more virulence genes were reported in DRC than was observed herein.

The findings of this study present a worrying presence of a rich repertoire of resistance and virulence genes as well as MGEs in clonal and multiclonal *E. coli* strains within Pretoria. Although no carbapenemase, *mcr* and *tet(X3/4)* genes respectively mediating resistance to carbapenems, colistin and tigecycline were found, the chromosomally mediated colistin and tigecycline resistance in some of the strains is a cause for concern. We recommend additional molecular surveillance studies to provide statistically stronger data to inform pertinent interventions to contain these MDR strains from further dissemination.
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